Cargando…

Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses

INTRODUCTION: Systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD) represent pediatric and adult variants of the Still’s disease continuum. To determine whether clinical outcomes between patients with sJIA and AOSD were similar, Bayesian and population model-based ana...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dunger-Baldauf, Cornelia, Nakasato, Priscila, Noviello, Stephanie, Whelan, Sarah, Bieth, Bruno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964916/ https://www.ncbi.nlm.nih.gov/pubmed/35044647 http://dx.doi.org/10.1007/s40744-021-00422-9

Ejemplares similares

Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease in the U.S. Real-World Settings
por: Hur, Peter, et al.
Publicado: (2021)

Treatment of systemic-onset juvenile arthritis with canakinumab
por: Peitz, Joachim, et al.
Publicado: (2015)

Development and Role in Therapy of Canakinumab in Adult-Onset Still’s Disease
por: Galozzi, Paola, et al.
Publicado: (2018)

Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
por: Wulffraat, NM, et al.
Publicado: (2014)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
por: Cavalli, Giulio, et al.
Publicado: (2019)

Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease
por: Vitale, Antonio, et al.
Publicado: (2020)

Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy
por: Brachat, Arndt H., et al.
Publicado: (2017)

Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis
por: Kostik, Mikhail M., et al.
Publicado: (2022)

Genes responding to Canakinumab therapy in SJIA are -inversely - disregulated in adult onset Still's disease
por: Brachat, A, et al.
Publicado: (2015)

Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
por: Cavalli, Giulio, et al.
Publicado: (2019)

Juvenile idiopathic arthritis with systemic onset with inflammatory bone lesions: two case reports of patients successfully treated with canakinumab and experience gained from literature
por: Alexeeva, Ekaterina I., et al.
Publicado: (2023)

PReS-FINAL-2169: Exposure-response modeling of canakinumab in the avoidance of flares in children with systemic juvenile idiopathic arthritis
por: Xiong, Y, et al.
Publicado: (2013)

Canakinumab and mycophenolate mofetil in managing proteinuria/renal amyloidosis secondary to adult-onset Still’s disease
por: Feng, Jin, et al.
Publicado: (2023)

An Update on the Pathogenic Role of Neutrophils in Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease
por: Kim, Ji-Won, et al.
Publicado: (2021)

Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still’s disease
por: Ruscitti, Piero, et al.
Publicado: (2022)

PReS-FINAL-2156: Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy
por: Nirmala, N, et al.
Publicado: (2013)

PReS-FINAL-2157: Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis
por: Quartier, P, et al.
Publicado: (2013)

PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients
por: Quartier, P, et al.
Publicado: (2013)

The Role of Interleukin 18/Interleukin 18-Binding Protein in Adult-Onset Still’s Disease and Systemic Juvenile Idiopathic Arthritis
por: Girard-Guyonvarc’h, Charlotte, et al.
Publicado: (2022)

“Online survey of COVID-19 immunization and infection in patients with systemic juvenile idiopathic arthritis and adult-onset still’s disease.”
por: Marques, Mariana Correia, et al.
Publicado: (2023)

Early Treatment of Systemic Juvenile Idiopathic Arthritis with Canakinumab and Complete Remission After 2 Years of Treatment Suspension: Case Report of an Adolescent Girl
por: Maggio, Maria Cristina, et al.
Publicado: (2019)

Foot and Ankle Conventional Radiography in Juvenile Idiopathic Arthritis: Does It Still Matter?
por: Posadzy, Magdalena, et al.
Publicado: (2022)

Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease
por: Sota, Jurgen, et al.
Publicado: (2019)

Roles of Interactions Between Toll-Like Receptors and Their Endogenous Ligands in the Pathogenesis of Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease
por: Jung, Ju-Yang, et al.
Publicado: (2020)

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials
por: Ruperto, Nicolino, et al.
Publicado: (2018)

Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study
por: Quartier, Pierre, et al.
Publicado: (2020)

The role of extracellular histones in systemic-onset juvenile idiopathic arthritis
por: Hu, Xiao, et al.
Publicado: (2019)

Treatment of patients with systemic-onset juvenile idiopathic arthritis with tacrolimus
por: Wang, Dongdong, et al.
Publicado: (2019)

Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity
por: Nirmala, Nanguneri, et al.
Publicado: (2015)

Canakinumab for the treatment of autoinflammatory very early onset- inflammatory bowel disease
por: Shaul, Eliana, et al.
Publicado: (2022)

Distinct Effects of Interleukin-1β Inhibition upon Cytokine Profile in Patients with Adult-Onset Still’s Disease and Active Articular Manifestation Responding to Canakinumab
por: Ghannam, Khetam, et al.
Publicado: (2021)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

Time of onset of iridocyclitis (IC) in children with juvenile idiopathic arthritis (JIA)
por: Verazza, S, et al.
Publicado: (2008)

MEFV mutations in Iranian children with systemic onset juvenile idiopathic arthritis
por: Farivar, Shirin, et al.
Publicado: (2014)

Monocytes and neutrophils in the inflammatory cascade of systemic onset Juvenile Idiopathic Arthritis
por: ter Haar, N, et al.
Publicado: (2015)

Tocilizumab-induced hypofibrinogenemia in patients with systemic-onset juvenile idiopathic arthritis
por: He, Tingyan, et al.
Publicado: (2023)

Application of the international league against rheumatism classification criteria for systemic juvenile idiopathic arthritis as a prognostic factor in patients with adults-onset Still’s disease
por: Yang, Ji Won, et al.
Publicado: (2018)

Juvenile idiopathic arthritis
por: Bhatt, Krupa H, et al.
Publicado: (2014)

Juvenile Idiopathic Arthritis
por: Barut, Kenan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ka1n22pg42ir17t7baqq86354f